Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis

Journal of the American Academy of Dermatology

Volumn 57, Issue 2, 2007, Pages 257-264

  Warshaw, Erin M ^a,b   Wohlhuter, Ross Jon ^a,b   Liu, An ^a   Zeller, Sarah A ^c   Wenner, Rachel A ^a,b   Bowers, Sacharitha ^a,b,d   Schultz, Julie C ^b   Katz, H Irving ^b   McCormick, Calogera L ^e   Parneix Spake, Anne ^e  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF OKLAHOMA   (United States)

^d SOUTHERN ILLINOIS UNIVERSITY   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PIMECROLIMUS;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SEBORRHEIC DERMATITIS; SKIN MANIFESTATION; STATISTICAL SIGNIFICANCE; STUDENT T TEST;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DERMATITIS, SEBORRHEIC; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG ERUPTIONS; FACIAL DERMATOSES; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; SEVERITY OF ILLNESS INDEX; TACROLIMUS; TREATMENT OUTCOME;

EID: 34447252806     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2006.11.007     Document Type: Article

References (28)

1. Hay R.J., and Graham-Brown R.A. Dandruff and seborrheic dermatitis: causes and management. Clin Exp Dermatol 22 (1997) 3-6
2. Gupta A.K., Nicol K., and Batra R. Role of antifungal agents in the treatment of seborrheic dermatitis. Am J Clin Dermatol 5 (2004) 417-422
3. Mirza S.H., Khan M.A., and Ahsan-ul-Haq M. Role of Malassezia yeast (pityrosporum) in seborrheic dermatitis (sd). J Coll Physicians Surg Pak 15 (2005) 771-773
4. Parry M.E., and Sharpe G.R. Seborrheic dermatitis is not caused by an altered immune response to Malassezia yeast. Br J Dermatol 139 (1998) 254-263
5. Cowley N.C., Farr P.M., and Shuster S. The permissive effect of sebum in seborrheic dermatitis: an explanation of the rash in neurological disorders. Br J Dermatol 122 (1990) 71-76
6. Furue M., Terao H., Rikihisa W., Urabe K., Kinukawa N., Nose Y., et al. Clinical dose and adverse effects of topical steroids in daily management of atopic dermatitis. Br J Dermatol 148 (2003) 128-133
7. Hugues J., and Rustin M. Corticosteroids. Clin Dermatol 15 (1997) 715-721
8. Hultsch T., Muller K.D., Meingassner J.G., Grassberger M., Schopf R.E., and Knop J. Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner. Arch Dermatol Res 290 (1998) 501-507
9. Zuberbier T., Chong S.U., Grunow K., Guhl S., Welker P., Grassberger M., et al. The ascomycin macrolactam pimecrolimus (pimecrolimus, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils. J Allergy Clin Immunol 108 (2001) 275-280
10. Eichenfield L.F., Lucky A.W., Boguniewicz M., Langley R.G., Cherill R., Marshall K., et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 46 (2002) 495-504
11. Ho V.C., Gupta A., Kaufmann R., Todd G., Vanaclocha F., Takaoka R., et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr 142 (2003) 155-162
12. Meurer M., Fartasch M., Albrecht G., Vogt T., Worm M., Ruzicka T., et al. Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis. Dermatology 208 (2004) 365-372
13. Wahn U., Bos J.D., Goodfield M., Caputo R., Papp K., Manjra A., et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 110 (2002) 1-8
14. Queille-Roussel C., Paul C., Duteil L., Lefebvre M.C., Rapatz G., Zagula M., et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol 144 (2001) 507-513
15. Pediatric Advisory Committee. Available at: URL:http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4089b2.htm. Accessed October 12, 2006.
16. Rigopoulos D., Ioannides D., Kalogeromitros D., Gregoriou S., and Katsambas A. Pimecrolimus cream 1% vs betamethasone 17-valerate 0.1% cream in the treatment of seborrheic dermatitis: a randomized open-label clinical trial. Br J Dermatol 151 (2004) 1071-1075
17. High W.A., and Pandya A.G. Pilot trial of 1% pimecrolimus cream in the treatment of seborrheic dermatitis in African American adults with associated hypopigmentation. J Am Acad Dermatol 54 (2006) 1083-1088
18. Rallis E., Nasiopoulou A., Kouskoukis C., and Koumantaki E. Pimecrolimus cream 1% an be an effective treatment for seborrheic dermatitis of the face and trunk. Drugs Exp Clin Res 30 (2004) 191-195
19. Firooz A., Solhpour A.M., Gorouhi F., Daneshpazhooh M., Balighi K., Farsinejad K., et al. Pimecrolimus cream 1% vs hydrocortone acetate cream 1% in the treatment of facial seborrheic dermatitis: a randomized investigator-blind, clincial trial. Arch Dermatol 142 (2006) 1066-1067
20. Crutchfield C.E. Pimecrolimus: a new treatment for seborrheic dermatitis. Cutis 70 (2002) 207-208
21. Brownell I., Quan L.T., and Hsu S. Topical pimecrolimus in the treatment of seborrheic dermatitis. Dermatol Online J 9 (2003) 13
22. Kapteine L, Karls R, Zigure S. Pimecrolimus cream 1% in the treatment of seborrheic dermatitis. Eur Acad Dermatol Venereol. Poster presentation. Available at: http://www.eadv2005.com/abstract/posters/P01.doc. Accessed November 28, 2006.
23. Cunha P.R. Pimecrolimus cream 1% is effective in seborrheic dermatitis refractory to treatment with topical corticosteroids. Acta Derm Venereol 86 (2006) 69-70
24. Chung J.H., Yano K., Lee M.K., Youn C.S., Seo J.Y., Kim K.H., et al. Differential effects of photoaging vs intrinsic aging on the vascularization of human skin. Arch Dermatol 138 (2002) 1437-1442
25. Dupuy P., Maurette C., Amoric J.C., and Chosidow O. Randomized, placebo-controlled, double-blind study on the clinical efficacy of ciclopiroxolamine 1% cream in facial seborrheic dermatitis. Br J Dermatol 144 (2001) 1033-1037
26. Gribetz C., Ling M., Lebwohl M., Pariser D., Draelos Z., Gottlieb A.B., et al. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J Am Acad Dermatol 51 (2004) 731-738
27. Gorman C.R., and White S.W. Rosaceiform dermatitis as a complication of treatment of facial seborrheic dermatitis with 1% pimecrolimus cream. Arch Dermatol 141 (2005) 1168
28. Ehst B., and Warshaw E.M. Alcohol-induced, application site-erythema after topical immunomodulator use and its inhibition by aspirin: report of a double-blind, controlled pilot trial. Arch Dermatol 140 (2004) 1014-1015